Moving the goal posts in prostate cancer trials
Mené sur 2 353 patients atteints d'un cancer de la prostate résistant à la castration de stade métastatique, cet essai multicentrique international évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout d'ortéronel à la prednisone
In The Lancet Oncology, Fred Saad and colleagues present final data from ELM-PC 4, a phase 3 trial of orteronel plus prednisone versus placebo plus prednisone in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer. Orteronel was developed to inhibit CYP17-mediated secondary androgen production via selective blocking of 17,20-lyase. Although abiraterone acetate has similar biological effects and is already approved for metastatic castration-resistant prostate cancer, orteronel represented another candidate androgen biosynthesis inhibitor.
The Lancet Oncology , commentaire, 2014